Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Retigabine - Bausch Health Companies/GlaxoSmithKline

Drug Profile

Retigabine - Bausch Health Companies/GlaxoSmithKline

Alternative Names: ADD-230001; AW21-360; D-20443; D-20443 dihydrochloride; D-23129; Ezogabine; Ezogabine-XR; GKE 841; GW-582892X; Potiga; Retigabine-XR; Trobalt; WAY-143841

Latest Information Update: 24 Oct 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Meda
  • Developer Bausch Health Companies; GlaxoSmithKline; Harvard University; Massachusetts General Hospital; The ALS Association; Valeant Pharmaceuticals International
  • Class Antiepileptic drugs; Carbamates; Fluorobenzenes; Phenylenediamines; Small molecules
  • Mechanism of Action GABA A receptor agonists; KCNQ potassium channel agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Market Withdrawal Partial epilepsies
  • Discontinued Amyotrophic lateral sclerosis; Lennox-Gastaut syndrome; Postherpetic neuralgia

Most Recent Events

  • 17 Jul 2018 GlaxoSmithKline terminates a phase III extension trial in Partial seizures (Adjunctive treatment) in Australia, France, Israel, Poland, Ukraine, Russia, South Africa, United Kingdom, Hungary, Belgium, Spain and Germany as there was no longer any benefit in collecting data since retigabine had been withdrawn from market (PO) (NCT00310388)
  • 13 Jul 2018 Valeant Pharmaceuticals International is now called Bausch Health Companies
  • 01 Feb 2018 Massachusetts General Hospital, in collaboration with GlaxoSmithKline, ALS Association and Harvard University completes a phase II trial in Amyotrophic lateral sclerosis in USA (PO) (NCT02450552)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top